Cargando…

Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

Detalles Bibliográficos
Autores principales:	Jiang, Tingting, Wang, Guan, Liu, Yao, Feng, Lu, Wang, Meng, Liu, Jie, Chen, Yi, Ouyang, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214051/ https://www.ncbi.nlm.nih.gov/pubmed/35755289 http://dx.doi.org/10.1016/j.apsb.2022.02.028

Ejemplares similares

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
por: Jiang, Tingting, et al.
Publicado: (2021)

Author correction to ‘Approved HIV reverse transcriptase inhibitors in the past decade’ [Acta Pharmaceutica Sinica B 12 (2022) 1567–1590]
por: Li, Guangdi, et al.
Publicado: (2023)

Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11(2021) 1903–1913]
por: Yu, Ziru, et al.
Publicado: (2023)

Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11 (2021) 1903–1913]
por: Yu, Ziru, et al.
Publicado: (2023)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

Author correction to “A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer’s disease” [Acta Pharmaceutica Sinica B 12, (2021) 4032–4044]
por: Lei, Ting, et al.
Publicado: (2022)

Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” [Acta Pharmaceutica Sinica B 12 (2022) 1523–1533]
por: Wu, Canhao, et al.
Publicado: (2023)

Author correction to ‘Up-regulation of glycolipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication’ [Acta Pharmaceutica Sinica B 9 (2019) 769–781]
por: Huang, Meng-Hao, et al.
Publicado: (2020)

Author correction to ‘Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome’ [Acta Pharmaceutica Sinica B 9 (2019) 734–744]
por: Wang, Zhilei, et al.
Publicado: (2020)

Author correction to ‘TMEM16A inhibits angiotensin II-induced basilar artery smooth muscle cell migration in a WNK1-dependent manner’ [Acta Pharmaceutica Sinica B 11 (2021) 3994–4007]
por: Zheng, Huaqing, et al.
Publicado: (2023)

Author correction to ‘Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy’ [Acta Pharmaceutica Sinica B 11 (2021) 3508–3526]
por: Wang, Shuyi, et al.
Publicado: (2023)

Author correction to ‘Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer’ [Acta Pharmaceutica Sinica B 2019; 9(5):1061–1077]
por: Mei, Dong, et al.
Publicado: (2020)

Author correction to ‘Design, synthesis and biological evaluation of chalcone analogues with novel dual antioxidant mechanisms as potential anti-ischemic stroke agents’ [Acta Pharmaceutica Sinica B 9 (2019) 335–350]
por: Wang, Jiabing, et al.
Publicado: (2022)

Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
por: Lai, Fangfang, et al.
Publicado: (2023)

Author correction to ‘Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling’ [Acta Pharmaceutica Sinica B 12 (2022) 1198–1212]
por: Wu, Yunhao, et al.
Publicado: (2022)

Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
por: Deng, Linglong, et al.
Publicado: (2023)

Erratum to “Identification of anti-Mycobacterium tuberculosis agents targeting the interaction of bacterial division proteins FtsZ and SepFe” [Acta Pharmaceutica Sinica B 13 (2023) 2056–2070]
por: Zhang, Hongjuan, et al.
Publicado: (2023)

Author correction to “Coordinated regulation of BACH1 and mitochondrial metabolism through tumor targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy” [Acta Pharmaceutica Sinica B 12 (2022) 3934–3951]
por: Yang, Xuan, et al.
Publicado: (2023)

Author correction to “DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS‒STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis” [Acta Pharmaceutica Sinica B 12 (2022) 262–273]
por: Wang, Yuanyuan, et al.
Publicado: (2023)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
por: Wang, Yuekun, et al.
Publicado: (2020)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

Author correction to ‘Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice’ [Acta Pharmaceutica Sinica B 13 (2023) 1164–1179]
por: Fan, Xiaoqing, et al.
Publicado: (2023)

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
por: Strohmeier, Simon, et al.
Publicado: (2021)

TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions
por: Cappellesso, Rocco, et al.
Publicado: (2022)

Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
por: Wong, Derek, et al.
Publicado: (2019)

Remarks from Editor-in-Chief on the celebration of the 65th anniversary of Acta Biochimica et Biophysica Sinica
por: Ding, Jianping
Publicado: (2023)

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
por: Liu, Fangfang, et al.
Publicado: (2022)

Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer
por: Klink, Andrew J., et al.
Publicado: (2022)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Scientia Pharmaceutica, Autorenhinweise 2013
Publicado: (2013)

Scientia Pharmaceutica, Autorenhinweise 2015
Publicado: (2015)

Scientia Pharmaceutica, Autorenhinweise 2016
Publicado: (2016)

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma
por: Wang, Hejing, et al.
Publicado: (2023)

Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer()()
por: Choi, Yuri, et al.
Publicado: (2018)

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
por: O’Reilly, E M, et al.
Publicado: (2019)

The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII
por: Farina, Antonietta Rosella, et al.
Publicado: (2018)

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
por: Schirrmacher, Ralf, et al.
Publicado: (2019)

Acknowledgement to Reviewers of Scientia Pharmaceutica in 2017
Publicado: (2018)

Infantile Fibrosarcoma With NTRK3–ETV6 Fusion Successfully Treated With the Tropomyosin‐Related Kinase Inhibitor LOXO‐101
por: Nagasubramanian, Ramamoorthy, et al.
Publicado: (2016)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_focnrdbe5mlpr6o5ousmq8hvsl